<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352103</url>
  </required_header>
  <id_info>
    <org_study_id>9220</org_study_id>
    <nct_id>NCT02352103</nct_id>
  </id_info>
  <brief_title>Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery</brief_title>
  <official_title>The Impact of Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy on Short-term Continence Recovery: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess and compare the short-term post-operative continence recovery rate in two cohorts
      of men undergoing Robot Assisted Radical Prostatectomy (RARP), each randomized to undergo
      RARP with Vattikuti Institute technique or Retzius sparing technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally, RARP is performed using a trans-peritoneal technique that pass anteriorly to
      the bladder. This technique necessitates the dissection and/or manipulation of many
      structures, which might compromise post-operative urinary continence recovery. These
      structures include the pubo-prostatic ligament, Santorini plexus, neurovascular bundle, and
      veil of Aphrodite. Recently, a &quot;Retzius-sparing&quot; technique to perform RARP has beed
      described. This approach passes posteriorly to the bladder, through the space of Douglas,
      which should minimize the damaged to the aforementioned structure. Theoretically, the latter
      technique should improve post-operative urinary continence recovery. However, a randomized
      comparison between the &quot;traditional&quot; RARP and &quot;Retzius-sparing&quot; RARP is still lacking.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">May 2032</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Continence Recovery</measure>
    <time_frame>One week after the removal of the suprapubic urinary catheter</time_frame>
    <description>24-hour pad weights</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urinary Continence Recovery</measure>
    <time_frame>within 3 months from the intervention</time_frame>
    <description>0 pad per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Peri and Postoperative Complications</measure>
    <time_frame>1-year median follow up</time_frame>
    <description>Clavien-Dindo complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Regained Potency Postoperatively (as Measured by Sexual Health Inventory for Men (SHIM) Score of 17 or Greater)</measure>
    <time_frame>1-year median follow up</time_frame>
    <description>SHIM ranges from 0-25 with higher scores indicating better sexual function; a score of &gt;=22 is normal and &gt;=17 is considered mild ED</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Biochemical Recurrence (Post-operative Prostate-Specific Antigen (PSA) Value &gt;=0.2 ng/ml)</measure>
    <time_frame>1-year median follow up</time_frame>
    <description>Patients without biochemical evidence of disease recurrence (i.e. postop PSA &gt;=0.2 ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Urinary Function and Urinary Function-related Quality of Life</measure>
    <time_frame>Within 3 months from the intervention</time_frame>
    <description>International Prostatic Symptom Score (continuous score from 0-35, higher scores indicating worse urinary function)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients Who Regained Urinary Continence Postoperatively</measure>
    <time_frame>1 year median follow up</time_frame>
    <description>0 pad per day</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-operative Urinary Function and Urinary Function-related Quality of Life</measure>
    <time_frame>1 year median follow up</time_frame>
    <description>MSKCC (Memorial Sloan Kettering Cancer Center) STAR questionnaire (symptom tracking and reporting). Score ranges from 0-25, with higher scores indicating better urinary function</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retzius sparing radical prostatectomy da Vinci Surgical System</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Retzius sparing radical prostatectomy</intervention_name>
    <description>Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vattikuti Urology Institute radical prostatectomy</intervention_name>
    <description>Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>da Vinci Surgical System</intervention_name>
    <description>The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with newly diagnosed prostate cancer undergoing robotic-assisted radical
             prostatectomy at the Vattikuti Urology Institute (performed by single surgeon, MM) as
             the primary treatment modality

          -  Be able to read and speak English and be able to provide written informed consent

        Exclusion Criteria:

          -  patients with high risk prostate cancer,defined as a biopsy Gleason score ≥8 and/or a
             pre-operative prostate specific antigen value ≥20 ng/ml.

          -  evidence of clinical nodal involvement (cN1) or metastatic disease (M1)

          -  patients participating in a competing study

          -  patients with pre-operative urinary incontinence.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mani Menon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford West Bloomfield Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <results_first_submitted>February 22, 2019</results_first_submitted>
  <results_first_submitted_qc>August 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2019</results_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Mani Menon</investigator_full_name>
    <investigator_title>Director, Vattikuti Urology Institute</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>Urinary continence</keyword>
  <keyword>robotic assisted radical prostatectomy</keyword>
  <keyword>Vattikuti Urology Institute (VIP) radical prostatectomy</keyword>
  <keyword>Retzius sparing radical prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Arm</title>
          <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Arm</title>
          <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Arm</title>
          <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Arm</title>
          <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" lower_limit="56" upper_limit="67"/>
                    <measurement group_id="B2" value="61" lower_limit="55" upper_limit="67"/>
                    <measurement group_id="B3" value="61" lower_limit="56" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="26.4" upper_limit="30.9"/>
                    <measurement group_id="B2" value="27.9" lower_limit="26.1" upper_limit="30.6"/>
                    <measurement group_id="B3" value="28" lower_limit="26.2" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>preoperative prostate specific antigen level</title>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" lower_limit="3.7" upper_limit="7.3"/>
                    <measurement group_id="B2" value="5.7" lower_limit="4.7" upper_limit="7.4"/>
                    <measurement group_id="B3" value="5.6" lower_limit="4.1" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>preoperative IPSS score</title>
          <description>International Prostatic Symptom Score (IPSS) objectively assesses urinary symptoms. It ranges from 0 to 35, with higher scores indicating worse urinary symptoms</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="B2" value="7" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="B3" value="7" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>preoperative SHIM score</title>
          <description>SHIM (Sexual Health Inventory for Men) objectively asses sexual function. It ranges from 0-25, with higher scores indicating better sexual function.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="8" upper_limit="25"/>
                    <measurement group_id="B2" value="20" lower_limit="14" upper_limit="24"/>
                    <measurement group_id="B3" value="20" lower_limit="11" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NCCN clinical risk</title>
          <description>NCCN (National Comprehensive Cancer Network) risk categorizes prostate cancer based on their likelihood of disease progression, recurrence and outcomes, into low, intermediate, high and very high risk groups. It uses clinical information (i.e information available PRIOR to surgery) for this (i.e PSA, biopsy gleason score and clinical T stage)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Low Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intermediate Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Continence Recovery</title>
        <description>24-hour pad weights</description>
        <time_frame>One week after the removal of the suprapubic urinary catheter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Continence Recovery</title>
          <description>24-hour pad weights</description>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="3" upper_limit="133"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urinary Continence Recovery</title>
        <description>0 pad per day</description>
        <time_frame>within 3 months from the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urinary Continence Recovery</title>
          <description>0 pad per day</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Peri and Postoperative Complications</title>
        <description>Clavien-Dindo complications</description>
        <time_frame>1-year median follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peri and Postoperative Complications</title>
          <description>Clavien-Dindo complications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Regained Potency Postoperatively (as Measured by Sexual Health Inventory for Men (SHIM) Score of 17 or Greater)</title>
        <description>SHIM ranges from 0-25 with higher scores indicating better sexual function; a score of &gt;=22 is normal and &gt;=17 is considered mild ED</description>
        <time_frame>1-year median follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Regained Potency Postoperatively (as Measured by Sexual Health Inventory for Men (SHIM) Score of 17 or Greater)</title>
          <description>SHIM ranges from 0-25 with higher scores indicating better sexual function; a score of &gt;=22 is normal and &gt;=17 is considered mild ED</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Biochemical Recurrence (Post-operative Prostate-Specific Antigen (PSA) Value &gt;=0.2 ng/ml)</title>
        <description>Patients without biochemical evidence of disease recurrence (i.e. postop PSA &gt;=0.2 ng/mL)</description>
        <time_frame>1-year median follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Biochemical Recurrence (Post-operative Prostate-Specific Antigen (PSA) Value &gt;=0.2 ng/ml)</title>
          <description>Patients without biochemical evidence of disease recurrence (i.e. postop PSA &gt;=0.2 ng/mL)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Urinary Function and Urinary Function-related Quality of Life</title>
        <description>International Prostatic Symptom Score (continuous score from 0-35, higher scores indicating worse urinary function)</description>
        <time_frame>Within 3 months from the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Urinary Function and Urinary Function-related Quality of Life</title>
          <description>International Prostatic Symptom Score (continuous score from 0-35, higher scores indicating worse urinary function)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.3" upper_limit="6.7"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.4" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients Who Regained Urinary Continence Postoperatively</title>
        <description>0 pad per day</description>
        <time_frame>1 year median follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Regained Urinary Continence Postoperatively</title>
          <description>0 pad per day</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post-operative Urinary Function and Urinary Function-related Quality of Life</title>
        <description>MSKCC (Memorial Sloan Kettering Cancer Center) STAR questionnaire (symptom tracking and reporting). Score ranges from 0-25, with higher scores indicating better urinary function</description>
        <time_frame>1 year median follow up</time_frame>
        <population>The numbers in this analyses are different from the primary analyses as some patients were lost to follow up (by one year)</population>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Urinary Function and Urinary Function-related Quality of Life</title>
          <description>MSKCC (Memorial Sloan Kettering Cancer Center) STAR questionnaire (symptom tracking and reporting). Score ranges from 0-25, with higher scores indicating better urinary function</description>
          <population>The numbers in this analyses are different from the primary analyses as some patients were lost to follow up (by one year)</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="23"/>
                    <measurement group_id="O2" value="20" lower_limit="17" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Arm</title>
          <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
Vattikuti Urology Institute radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Arm</title>
          <description>Retzius sparing radical prostatectomy da Vinci Surgical System
Retzius sparing radical prostatectomy: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
da Vinci Surgical System: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pelvic hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small Bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deepansh Dalela, MD</name_or_title>
      <organization>Vattikuti Urology Institute, Henry Ford Hospital</organization>
      <phone>3139162600</phone>
      <email>ddalela1@hfhs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

